Galvokimig - UCB Biopharma
Alternative Names: Galvokimig-UCB Biopharma; UCB-9741Latest Information Update: 10 Feb 2025
At a glance
- Originator UCB Biopharma
- Class Anti-inflammatories; Antibodies; Bispecific antibodies; Skin disorder therapies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Atopic dermatitis
Most Recent Events
- 01 Jan 2025 UCB Biopharma completes a phase I trial in (indication) in Atopic dermatitis (In volunteers) in USA (SC) (NCT06315335)
- 01 Jul 2024 Phase-I clinical trials in Atopic dermatitis (In volunteers) in USA (SC) (NCT06315335)
- 06 Jun 2024 UCB Biopharma completes phase I/II clinical trials in Atopic dermatitis in Netherlands, Germany, Bulgaria (IV) (SC) (NCT04643457)